Introduction
============

Colorectal cancer (CRC) is the most common malignancy throughout the world,[@b1-cmar-10-2871] and liver metastases are the major cause of death in CRC patients. Unfortunately, 40%--50% of CRC patients would develop colorectal liver metastases (CLMs). They are either synchronous or metachronous in presentation with approximately equal incidence.[@b2-cmar-10-2871],[@b3-cmar-10-2871] Compared with synchronous metastases, patients with metachronous metastases show differences in terms of clinicopathologic characteristics and better prognosis after metastases resections.[@b4-cmar-10-2871]--[@b6-cmar-10-2871] However, in previous studies, synchronous and metachronous liver metastases were usually lumped together, neglecting their clinical and biologic differences. It is critical to improve our understanding of the biology of liver metastases, which may help to develop more effective therapeutic strategies.

Biologic differences between synchronous and metachronous CLMs had been studied previously but showed conflicting results.[@b2-cmar-10-2871],[@b7-cmar-10-2871]--[@b11-cmar-10-2871] Available evidence indicated that majority of gene alterations in the primary tumor were maintained in the CLMs, whereas a limited number of studies compared the primary tumors of synchronous and metachronous groups and generally demonstrated no differences in biomarker expression. In consideration of limited number of studies and limited number of biomarkers investigated, it is still not reasonable to deny the hypothesis that the biology of synchronous and metachronous CLMs would be different in view of the known clinicopathologic differences that exist between them. Thus, more comprehensive researches are needed. The use of next-generation sequencing (NGS) for high-throughput genomic analysis has accelerated our understanding of the molecular characteristics of CRC[@b12-cmar-10-2871]--[@b14-cmar-10-2871] and may also serve us an insight on this topic.

Therefore, we conducted NGS of primary tumors of synchronous or metachronous CLM to investigate mutational patterns between them. We also expected to find prognostic or predictive biomarkers among mutations sequenced.

Patients and methods
====================

Study population
----------------

This study retrospectively included patients with CRC treated at General Surgery Department of Zhongshan Hospital, Fudan University (Shanghai, China) during June 2008 to December 2014. The inclusion criteria were as follows: colorectal adenocarcinoma determined by pathologic evidence; wild-type RAS; liver metastases determined by radiologic and/or pathologic evidence; radical resections of primary tumors; enough formalin-fixed paraffin-embedded (FFPE) tissue of primary tumors; no exposure to any treatment (chemotherapy, targeted therapy, radiotherapy, or interventional therapy) before primary tumor resections. Patients with liver metastases accompanied with other distant metastases were permitted. Adjuvant chemotherapy after primary tumor resection was permitted. Target therapy and interventional therapy were permitted only after the occurrence of liver metastases. All patients provided written and oral informed consent. This study was approved by the ethics committee of Zhongshan Hospital, Fudan University.

Two groups were established in this study: the synchronous-metastases group and the metachronous-metastases group. The synchronous-metastases group consisted of patients with liver metastases diagnosed together with or within a 6-month interval of the diagnosis of the primary colorectal tumor. The metachronous-metastases group consisted of patients with liver metastases diagnosed \>6 months after primary tumor resection. This study was approved by the local ethics committees and all patients provided written and oral informed consent, including research on tumor tissue.

In addition, 10 patients were selected for whole-exome sequencing (WES). All 10 patients were diagnosed with CLM and underwent resection of both primary and metastatic tumors. Exclusion criteria included previous exposure to any treatment for metastatic CRC, family history of CRC, and evidence of a mismatch repair deficiency.

Study procedure
---------------

To investigate mutational pattern of different liver metastases, we examined biomarkers (single-nucleotide polymorphism, SNP) through genome-wide exploration using NGS. To preliminarily select genes to construct a custom panel for target capture sequencing, we performed WES for 10 triplets, each comprising primary colorectal tumor and normal colorectal mucosa and matched liver metastases. Genomic DNA from fresh tissue was samples sequenced on an Ion™ Proton (Life Technologies, Carlsbad, CA, USA) platform according to the manufacturer's instructions. Normal colorectal mucosa was sequenced to exclude germline variants. The read alignments and variant analyses were performed according to the predefined workflow.

We constructed a custom panel of 96 genes selected based on driver mutations identified using WES and Tumor Mutation Hotspots Panel version 2 (Life Technologies, Carlsbad, CA, USA). Genomic DNA from FFPE tissue samples of patients in both cohorts was subsequently sequenced for SNPs using an Ion™ Torrent Personal Genome Machine (PGM) according to the manufacturer's instructions. For a given gene loci, the fraction of mutant alleles was calculated by diving the number of mutant reads by the number of total reads. A 5% cutoff value was employed. A sample was considered wild-type for a given gene when all sequenced loci harbored \<5% mutant alleles.

Whole-exome sequencing
----------------------

DNA was extracted from fresh tumor samples using the MELT™ Total Nucleic Acid Isolation Kit (Life Technologies). Quantity and quality were assessed using Qubit 2.0 (Life Technologies). Fifty to hundred nanograms of DNA for each sample was used for exome capture and library preparation with Ion AmpliSeq™ Exome Kit 4xDuo (Life Technologies) following the manufacturer's instructions. Then libraries were bar-coded with Ion Xpress™ Barcode Adapters Kit (Life Technologies). The concentration of each library was determined by PCR with the Ion Library™ Quantization Kit (Life Technologies). According to the manufacturer's instructions, all libraries were diluted to 100 pM working solutions and then pooled as needed to perform the template preparation with Ion PI™ Template OT2 200 kit v2 (Life Technologies) on Ion One Touch™ 2 System. Quality and quantity were determined with Qubit Ion Sphere™ Quality Control Kit (Life Technologies) for the obtained ion sphere particles. WES was performed on Ion Proton™ platform, using the Ion PI™ Sequencing 200 kit v2 and Ion PI™ Chip kit v2. Sequencing data were analyzed with the Torrent Suite™ Software v4.0 (Life Technologies) using default parameters setting.

Processing of WES data
----------------------

The primary WES data were analyzed for single-nucleotide variants (SNVs) following the procedures indicated below. Variants with SNV quality (QUAL) ≤20 were excluded. QUAL was calculated using Torrent Suite™ software.Variants of normal mucosa were considered background variants. Primary or metastatic tumor samples were filtered using background variants, and the variants were rejected as germline variants or sequencing artifacts when present in the corresponding normal samples.Primary or metastatic tumor-specific SNVs were analyzed using the SeattleSeq SNP Annotation.[@b15-cmar-10-2871] Known germline mutations from the Exome Sequencing Project[@b16-cmar-10-2871] and dbSNP databases (build 140)[@b17-cmar-10-2871] were also excluded. We selected nonsilent mutations, including missense mutations and InDels.Nonsilent mutations were predicted to affect gene function when any of the following criteria were fulfilled: 1) functional impact score of SIFT[@b18-cmar-10-2871] ≤0.05;[@b19-cmar-10-2871] 2) functional impact score of PolyPhen-2[@b20-cmar-10-2871] \>0.45;[@b21-cmar-10-2871] 3) functional impact label of Mutation Assessor[@b22-cmar-10-2871] was "medium" or "high";[@b23-cmar-10-2871] 4) Condel[@b24-cmar-10-2871] label was "deleterious";[@b25-cmar-10-2871] and 5) functional impact score of FATHMM[@b26-cmar-10-2871] \<0.[@b27-cmar-10-2871]The transFIC analysis was performed as previously described.[@b28-cmar-10-2871] Mutations were considered cancer driver mutations when the outcome of the transFIC analysis was of "high impact".

Construction of custom panel
----------------------------

To prepare for target capture sequencing, we constructed a custom panel based on WES data and Tumor Mutation Hotspots Panel version 2. When selecting genes from WES data, genes that were essential for cancer progression, particularly liver metastasis, were considered with priority. On one hand, we searched all mutations in the GeneRIF database[@b29-cmar-10-2871] using key words "cancer/tumor/carcinoma" and "metasta-/invasion/invade/invasive/migrate". On the other hand, we focused on mutations of universal genes in primary tumors and corresponding liver metastases. In addition, most genes in the Tumor Mutation Hotspots Panel version 2 were included. The mutation information for these genes was acquired from the Catalog of Somatic Mutations in Cancer (COSMIC) database,[@b30-cmar-10-2871] and we employed the most frequent mutations to build the panel.

Target capture sequencing
-------------------------

DNA was extracted from FFPE tumor samples using the RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies) according to the manufacturer's instructions. Quantity and quality were assessed using Qubit 2.0 (Life Technologies). Ten nanograms of DNA for each sample was used for library construction and template preparation with same procedures described above in the "Whole-exome sequencing" section. Target capture sequencing was carried out with customized panel using the Ion PGM™ platform (Life Technologies) according to the manufacturer's instructions. The panel consisted of two separate PCR primer pools covering recurrent mutations in 96 genes with 1500X sequence coverage on Ion™ 318 chip. Sequencing data were analyzed with Ion Reporter™ software v4.4 (Life Technologies) using default parameters setting.

Statistical analysis
--------------------

The statistical analysis plan was established before the genotyping results were available. Differences in categorical parameters were calculated using a chi-square test or Fisher's exact test. Survival curves were generated using the Kaplan--Meier method and compared using a log-rank test. Hazard ratios and 95% CIs were calculated using the Cox proportional hazards model. For univariate and multivariate analyses of latency of metachronous liver metastases, the Cox proportional hazards model was used. All statistical analyses were conducted using the statistical software SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A *p*-value \<0.05 was considered statistically significant.

Results
=======

Patients and clinical characteristics
-------------------------------------

A total of 161 patients were included and sequenced. According to the metastatic type, 93 patients were in synchronous-metastases group and 68 patients in metachronous-metastases group. Several differences in clinical characteristics were observed between groups ([Table 1](#t1-cmar-10-2871){ref-type="table"}). Patients with metachronous CLMs were obviously elder. With regard to pathology of primary tumors, synchronous CLMs were larger in size, poorly differentiated, and more frequently local advanced and lymph node positive. As to evaluation of liver metastases, synchronous CLMs result in more and larger metastatic lesions.

Summary of WES and target capture sequence
------------------------------------------

Ten triplets were sequenced with WES for preliminarily data to construct custom panel. Overall, we identified 608 potential somatic driver mutations in 511 genes in primary colorectal tumors and 694 potential somatic driver mutations in 638 genes in liver metastases. The number of somatic mutations in 10 primary colorectal tumor ranged from 41 to 87, with a mean of 60 ([Figure 1A](#f1-cmar-10-2871){ref-type="fig"}), which was not significantly different from that of the non-hypermutated CRCs reported in The Cancer Genome Atlas.[@b31-cmar-10-2871] When comparing mutations between tumors, 230 mutations in 219 genes were universal in the primary tumor and corresponding liver metastases. In addition, mutations observed in 10 patients were predominated by the C/G\>T/A transition ([Figure 1B](#f1-cmar-10-2871){ref-type="fig"}) consistent with the results of previous CRC genomics studies.[@b31-cmar-10-2871],[@b32-cmar-10-2871]

According to the custom panel, 161 patients were sequenced with target capture sequence for recurrent mutations of 96 genes. Mutations with mutational frequencies \>10% and \<90% were further investigated for stability. Finally, 48 mutations in 27 genes were included in following analysis ([Table 2](#t2-cmar-10-2871){ref-type="table"}). Among these mutations, 40 were already documented in dbSNP databases (build 140).

Correlation between clinical characteristics and mutations
----------------------------------------------------------

Univariate analysis identified that 18 mutations in 12 genes were correlated with clinical variables ([Table 3](#t3-cmar-10-2871){ref-type="table"}). MDC1 was associated with the most number of clinical variables, including T stage, N stage, tumor location of primary, and size and number of liver metastases. Mutations of ATAD3B, MAGEC1, and MICB were only associated with pathologic variables of primary tumor. Most of the mutations associated with variables of liver metastases were also associated with lymph node metastases. Ten correlations with preoperative CEA level, lymph node metastases, and number of LMs remained significant with false discovery rate \<0.05.

Mutational pattern of synchronous and metachronous liver metastases
-------------------------------------------------------------------

The median number of mutations in the synchronous group was 22 (range from 2 to 32), which was significantly higher than 18 (range from 2 to 28) in the metachronous group (*p*\<0.001). Mutation frequency of the synchronous group, compared with the metachronous group, was significantly higher in 12 mutations and lower in five mutations ([Figure 2](#f2-cmar-10-2871){ref-type="fig"}). For most other mutations, the frequency was numerically higher in the synchronous group. In addition, only half of the most prevalent mutations in the synchronous group were in common with that in the metachronous group ([Table 4](#t4-cmar-10-2871){ref-type="table"}).

Mutations and survival of metachronous liver metastases
-------------------------------------------------------

The latency of metachronous CLMs is summarized in [Figure 3](#f3-cmar-10-2871){ref-type="fig"}. Half of all metachronous CLMs occurred within 15 months, and 75% occurred within 24 months. For patients with metachronous CLMs, the latency was significantly associated with prevalent mutations in metachronous CLMs, including EGFR rs2227983, RBMXL3 rs12399211, TAPBP rs2071888, PTPN23 c.3361A\>T, PTCH1 rs357564, and MDC1 rs61733213. In multivariate analysis, correlation between latency and EGFR rs2227983, RBMXL3 rs12399211, and PTCH1 rs357564 remained significant ([Table 5](#t5-cmar-10-2871){ref-type="table"}).

Discussion
==========

In this study, we conducted NGS in primary tumors of synchronous or metachronous CLM and identified several differences in terms of clinical characteristics and mutational patterns.

For clinicopathologic characteristics, our results were broadly consistent with previous studies.[@b2-cmar-10-2871],[@b5-cmar-10-2871] Patients from the synchronous group were younger than those from the metachronous group. Compared to the metachronous group, patients in the synchronous group showed heavier tumor burden for both primaries and liver metastases. Furthermore, the synchronous group, more frequently characterized by adverse prognostic factors, had inferior overall survival than the metachronous group (median time 26 vs. 36 months, *p*=0.001). These results indicated that synchronous CLM may represent a more aggressive tumor subtype than metachronous CLM. All these issues highlight the need for understanding of differences in molecular biology, which results in and keeps the different manifestations between synchronous and metachronous CLMs.

Based on the understanding of the mechanisms of metastases, we extracted our efforts to identify biologic differences between synchronous and metachronous CLMs. In contrast to previous studies focusing on limited gene alterations,[@b2-cmar-10-2871],[@b8-cmar-10-2871],[@b9-cmar-10-2871],[@b33-cmar-10-2871] we used a multivariable approach, including genome-wide exploration using WES, panel construction based on bioinformatics, and selection of significant biomarkers according to clinical outcomes. The advantage of this multivariable approach is that it is unbiased by biologic assumptions and thereby may find correlations between distinct gene mutations and liver metastases.

Finally, we included and analyzed 48 mutations in 27 genes. The synchronous group harbored significantly more mutations than the metachronous group, representing a more heterogeneous and advanced subgroup of CLM. For the synchronous group, about half of the prevalent mutations were in common with the metachronous group, and the most prevalent was EGFR rs2227983. These mutations were potential key mutations of liver metastases and further research was needed. Another half of the prevalent mutations were private in the synchronous group and were significantly more frequently mutant than the metachronous group. In addition, prevalent mutations private in the metachronous group showed similar trend. Furthermore, these mutations, including RBMXL3 rs12399211, PTPN23 c.3361A\>T, PTCH1 rs357564, and MDC1 rs61733213, partly explained the latency of metachronous liver metastases. All these results indicated that the synchronous and the metachronous groups showed different mutational patterns, and these mutations were correlated with several clinical characteristics. Different mutations may be potential key mutations and further researches were needed.

In previous studies on this topic, the majority found differences in molecular marker expression between CLMs and their respective primaries in both the synchronous and metachronous groups. Limited comparison was done between LMs or primaries between the synchronous and the metachronous groups. Pantaleo et al[@b8-cmar-10-2871] compared the expression signature with reverse transcriptase PCR and enzyme-linked immunosorbent assay and indicated that EGFR and COX-2 are overexpressed in metachronous and synchronous metastases, respectively. van der Wal et al[@b2-cmar-10-2871] reported that liver parenchyma adjacent to the LMs provides a highly prosperous angiogenic environment in the synchronous group compared to the metachronous groups. However, there were also many studies with negative findings.[@b34-cmar-10-2871],[@b35-cmar-10-2871] Our results added evidences for the hypothesis that synchronous and metachronous CLMs were biologically different.

According to previous studies, both synchronous and metachronous CLMs would evolve different biologic alterations to their corresponding primaries.[@b11-cmar-10-2871],[@b32-cmar-10-2871],[@b33-cmar-10-2871],[@b36-cmar-10-2871] Thus, examination of metastatic tissue is crucial as it could help choose optimal treatment according to current biologic status. Simultaneously, studies also demonstrated that the majority of biologic alterations, especially key alterations, in primaries were maintained in CLMs.[@b11-cmar-10-2871],[@b32-cmar-10-2871],[@b35-cmar-10-2871] If these key alterations of liver metastases could be detected in primaries, it could have important clinical implications for prediction of occurrence, even timing of liver metastases. Under consideration of the evidence mentioned above, we selected and examined tissue of primary tumors. If only corresponding metastatic tissue were examined, our study may provide more information.

This was a retrospective exploratory study and there were several limitations: first, we sequenced single type of gene alteration in a highly selected cohort. Only SNPs of primary tumors with wild-type RAS were sequenced. Thus, this study provided an incomplete and partial view on differences between different CLMs; second, many correlations were observed between clinical parameters and mutations, but relevant biologic evidences were still limited. More studies were needed to confirm the clinical meanings and explore the underlying mechanism. Third, the influences of tumor heterogeneity and differences between LMs and their respective primaries were not taken into consideration in the study.

Conclusion
==========

Synchronous CLMs, compared to metachronous CLMs, were younger and showed heavier tumor burden for both primaries and liver metastases. NGS identified different mutational patterns between synchronous and metachronous CLMs. Further researches were needed to confirm the correlation between differences in clinical characteristics and mutational patterns and the mechanism inside.
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![Summary of driver mutations identified by whole-exome sequencing.\
**Notes:** (**A**) Distribution of driver mutations in primary tumor and liver metastases. (**B**) Distribution of transitions and transversions.\
**Abbreviations:** L, liver metastases; P, primary tumor.](cmar-10-2871Fig1){#f1-cmar-10-2871}

![Mutation frequencies of synchronous and metachronous CLMs.\
**Notes:** (**A**) Mutation frequency of most sequenced genes were different between synchronous and metachronous CLMs, and 17 of them were statistically signifcant. (**B**) Synchronous CLMs carried significantly more mutations than metachronous CLMs (median number, 22 vs 18, *p*\<0.001).\
**Abbreviation:** CLMs, colorectal liver metastases.](cmar-10-2871Fig2){#f2-cmar-10-2871}

![Timing of metachronous metastases.\
**Note**: Half of all metachronous colorectal liver metastases occurred within 15 months, and 75% occurred within 24 months.](cmar-10-2871Fig3){#f3-cmar-10-2871}

###### 

Clinical characteristics of synchronous and metachronous groups

  -------------------------------------------------------------------------------------------------
  Clinical variables                                     Synchronous\   Metachronous\   *p*-value
                                                         (N=93)         (N=68)          
  ------------------------------------------------------ -------------- --------------- -----------
  Age (years), mean±SD                                   55.1±10.3      63.4±11.8       \<0.001

  Gender, n (%)                                                                         0.652

   Male                                                  62 (66.7%)     43 (63.2%)      

   Female                                                31 (33.3%)     25 (36.8%)      

  CEA level at diagnosis, ng/mL, n (%)                                                  \<0.001

   ≥5                                                    79 (84.9%)     21 (30.9%)      

   \<5                                                   14 (15.1%)     47 (69.1%)      

  Primary tumor location, n (%)                                                         0.428

   Right-sided                                           30 (32.3%)     18 (26.5%)      

   Left-sided                                            63 (67.7%)     50 (73.5%)      

  Tumor diameter (cm), mean±SD                           5.1±2.1        4.2±1.8         0.011

  Histologic grade, n (%)                                                               0.016

   Well (Grade 1)                                        2 (2.2%)       7 (10.3%)       

   Moderate (Grade 2)                                    59 (63.4%)     48 (70.6%)      

   Poor (Grades 3 and 4)                                 32 (34.4%)     13 (19.1%)      

  pT stage, n (%)                                                                       0.004

   T1/T2                                                 3 (3.2%)       13 (19.1%)      

   T3/T4                                                 90 (96.8%)     55 (80.9%)      

  pN stage, n (%)                                                                       \<0.001

   N0                                                    15 (16.1%)     43 (63.2%)      

   N1                                                    43 (46.2%)     18 (26.5%)      

   N2                                                    35 (37.6%)     7 (10.1%)       

  Tumor deposits, n (%)                                                                 0.001

   No                                                    47 (50.5%)     53 (77.9%)      

   Yes                                                   46 (49.5%)     15 (22.1%)      

  Distribution of LM, n (%)                                                             \<0.001

   Unilobar                                              34 (36.5%)     47 (69.1%)      

   Bilobar                                               59 (63.5%)     21 (30.9%)      

  Numbers of LM                                                                         \<0.001

   Median (IQR)                                          5 (3--10)      2 (1--4)        

  Diameter of the largest                                                               0.007

  LM, cm                                                                                

   Median (IQR)                                          38 (27--69)    33 (14--52)     

  Accompany with other metastases, n (%)                                                

   Lung                                                  10 (12.9%)     5 (7.3%)        0.764

   Retroperitoneal LN                                    6 (6.4%)       2 (2.9%)        0.598

   Others[\*](#tfn1-cmar-10-2871){ref-type="table-fn"}   3 (3.2%)       2 (2.9%)        0.995
  -------------------------------------------------------------------------------------------------

**Note:**

Includes omentum, ovary, and brain.

**Abbreviations:** CEA, carcinoembryonic antigen; IQR, interquartile range; LM, liver metastases; LN, lymph node.

###### 

List of mutations analyzed

  Gene         Single Nucleotide Polymorphism database (dbSNP)   cDNA    Coding sequence (CDS)   Protein   Amino acids   Codons
  ------------ ------------------------------------------------- ------- ----------------------- --------- ------------- ---------
  *ACTN4*      --                                                1,276   1,200                   400       W/C           tgG/tgC
  *ATAD3B*     rs860213                                          1,273   1,157                   386       R/Q           cGg/cAg
  *ATAD3B*     rs139902189                                       1,851   1,735                   579       R/C           Cgc/Tgc
  *ATP6V1B1*   rs17720303                                        162     89                      30        T/I           aCc/aTc
  *COL2A1*     rs2070739                                         4,378   4,213                   1,405     G/S           Ggc/Agc
  *CUL9*       rs2273709                                         5,918   5,843                   1,948     H/P           cAc/cCc
  *EGFR*       rs2227983                                         1,586   1,403                   468       R/K           aGg/aAg
  *ERBB2*      rs1058808, rs370420724                            3,463   3,463                   1,155     P/A           Ccc/Gcc
  *ERBB2*      rs1136201                                         281     283                     95        I/V           Atc/Gtc
  *EZH2*       rs2302427                                         648     526                     176       D/H           Gac/Cac
  *FAM129A*    --                                                2,020   1,826                   609       L/P           cTg/cCg
  *FCGBP*      rs11083543                                        4,026   4,018                   1,340     V/L           Gtg/Ctg
  *FCGBP*      rs75388508                                        52      44                      15        T/N           aCc/aAc
  *HNF1A*      rs1169288                                         222     223                     75        I/L           Atc/Ctc
  *KRT33A*     rs12937519                                        854     809                     270       A/V           gCg/gTg
  *LAMA4*      rs1050349                                         3,754   3,356                   1,119     P/R           cCt/cGt
  *LY6G6D*     rs118062293                                       334     334                     112       R/C           Cgt/Tgt
  *MAGEC1*     rs12558365                                        1,008   722                     241       S/F           tCc/tTc
  *MAGEC1*     rs176037                                          738     452                     151       T/I           aCt/aTt
  *MAP3K19*    rs3905317                                         2,466   2,435                   812       E/G           gAa/gGa
  *MAP3K19*    rs1112542                                         2,057   2,026                   676       E/Q           Gag/Cag
  *MDC1*       --                                                5,320   4,672                   1,558     G/S           Ggc/Agc
  *MDC1*       rs144087810                                       6,265   5,617                   1,873     P/A           Ccc/Gcc
  *MDC1*       rs61733213                                        4,595   3,947                   1,316     M/R           aTg/aGg
  *MDC1*       rs9461623                                         719     721                     241       S/P           Tct/Cct
  *MDC1*       --                                                1,975   1,535                   512       R/K           aGa/aAa
  *MDN1*       rs4707569                                         1,434   1,318                   440       F/V           Ttt/Gtt
  *MEGF6*      rs7513275                                         571     344                     115       M/T           aTg/aCg
  *MEGF6*      rs7553399                                         2,974   2,747                   916       R/L           cGg/cTg
  *MEGF6*      rs4648506                                         3,637   3,410                   1,137     G/A           gGc/gCc
  *MICB*       rs1065075                                         346     238                     80        K/E           Aag/Gag
  *MICB*       rs1051788                                         451     310                     104       D/N           Gat/Aat
  *MICB*       rs3134900                                         408     267                     89        I/M           atC/atG
  *PTCH1*      rs357564                                          4,086   3,941                   1,314     P/L           cCc/cTc
  *PTPN23*     rs6780013                                         2,788   2,452                   818       A/T           Gca/Aca
  *PTPN23*     --                                                3,697   3,361                   1,121     S/C           Agc/Tgc
  *RBMXL3*     rs12399211                                        1,234   1,192                   398       D/N           Gac/Aac
  *RBMXL3*     --                                                3,059   3,017                   1,006     G/D           gGc/gAc
  *RBMXL3*     rs6643947                                         3,187   3,145                   1,049     R/G           Agg/Ggg
  *TAPBP*      rs2071888                                         731     518                     173       T/R           aCa/aGa
  *TAPBP*      --                                                421     208                     70        V/M           Gtg/Atg
  *TAPBP*      --                                                597     251                     84        R/P           cGg/cCg
  *TCF3*       rs2074888                                         1,972   1,475                   492       A/V           gCg/gTg
  *TYK2*       rs2304256                                         1,566   1,084                   362       V/F           Gtc/Ttc
  *WDSUB1*     rs7591849                                         1,107   958                     320       R/S           Cgc/Agc
  *WDSUB1*     rs16843852                                        793     644                     215       K/T           aAa/aCa
  *ZNF462*     rs3814538                                         5,772   5,483                   1,828     N/S           aAc/aGc
  *ZNF462*     rs17723637                                        1,499   1,210                   404       M/V           Atg/Gtg

###### 

Clinical variables associated with gene mutations

  Clinical variable             Mutation             Mutation frequency (vs. no risk variable)   *p*-value   *q*-value
  ----------------------------- -------------------- ------------------------------------------- ----------- -----------
  Age ≥65 years                 PTPN23 c.3361A\>T    60.5% (26/43) (vs. 33.9% \[40/118\])        0.002       0.096
  Male gender                   KRT33A rs12937519    59.0% (62/105) (vs. 41.1% \[23/56\])        0.030       0.480
                                MAGEC1 rs176037      23.8% (25/105) (vs. 42.9% \[24/56\])        0.012       0.576
                                MICB rs3134900       8.6% (9/105) (vs. 21.4% \[12/56\])          0.012       0.288
  CEA at diagnosis ≥5 ng/mL     ATAD3B rs860213      62% (62/100) (vs. 32.8% \[20/61\])          \<0.001     0.008
                                TCF rs2074888        68% (68/100) (vs. 49.2% \[30/61\])          0.018       0.144
                                MAP3K19 rs3905317    61% (61/100) (vs. 42.6% \[26/61\])          0.023       0.159
                                COL2A1 rs2070739     64% (64/100) (vs. 47.5% \[29/61\])          0.040       0.192
                                MEGF6 rs7513275      51% (51/100) (vs. 26.2% \[16/61\])          0.002       0.032
                                MDC1 c.4672G\>A      53% (53/100) (vs. 36.1% \[55/61\])          0.037       0.196
                                PTPN23 c.3361A\>T    30% (30/100) (vs. 59.0% \[36/61\])          \<0.001     0.012
                                MDC1 rs61733213      29% (29/100) (vs. 47.5% \[29/61\])          0.017       0.163
                                MAGEC1 rs176037      22% (22/100) (vs. 44.3% \[27/61\])          0.003       0.036
                                MDC1 c.1535G\>A      10% (10/100) (vs. 23.0% \[14/61\])          0.025       0.150
  Right-sided tumors            MDC1 c.4672G\>A      62.5% (30/48) (vs. 39.8% \[45/113\])        0.008       0.384
  Poor histologic grade         ATAD3B rs860213      64.4% (29/45) (vs. 45.7% \[53/116\])        0.033       0.528
                                KRT33A rs12937519    68.9% (31/45) (vs. 46.6% \[54/116\])        0.011       0.528
                                ATAD3B rs139902189   44.4% (20/45) (vs. 26.7% \[31/116\])        0.030       0.720
                                MAGEC1 rs12558365    33.3% (15/45) (vs. 18.1% \[21/116\])        0.037       0.444
  T3/T4                         MICB rs1065075       33.8% (49/145) (vs. 62.5% \[10/16\])        0.024       0.576
                                MICB rs3134900       11.0% (16/145) (vs. 31.3% \[5/16\])         0.023       --
  Lymph node positive           ATAD3B rs860213      59.2% (61/103) (vs. 36.2% \[21/58\])        0.005       0.048
                                MEGF6 rs7513275      47.6% (49/103) (vs. 31.0% \[18/58\])        0.041       0.246
                                RBMXL3 rs12399211    53.4% (55/103) (vs. 75.9% \[44/58\])        0.005       0.060
                                MDC1 rs144087810     38.8% (40/103) (vs. 13.8% \[8/58\])         0.001       0.024
                                PTPN23 c.3361A\>T    29.1% (30/103) (vs. 62.1% \[36/58\])        \<0.001     0.020
                                MDC1 rs61733213      27.2% (28/103) (vs. 51.7% \[30/58\])        0.002       0.032
                                MAGEC1 rs176037      23.3% (24/103) (vs. 43.1% \[25/58\])        0.009       0.617
                                MICB rs3134900       7.8% (8/103) (vs. 22.4% \[13/58\])          0.008       0.064
  Numbers of LM ≥median level   MEGF6 rs7513275      47.8% (54/113) (vs. 27.1% \[13/48\])        0.015       0.240
                                RBMXL3 rs12399211    54.0% (61/113) (vs. 79.2% \[38/48\])        0.003       0.072
                                MDC1 rs144087810     34.5% (39/113) (vs. 18.8% \[9/48\])         0.045       0.540
                                PTPN23 c.3361A\>T    32.7% (37/113) (vs. 60.4% \[29/48\])        0.001       0.038
  Diameter of the largest LM    HNF1A 1rs1169288     68.8% (64/93) (vs. 48.5% \[33/68\])         0.009       0.413
  ≥median level                 MDC1 c.4672G\>A      53.8% (50/93) (vs. 36.8% \[25/68\])         0.033       0.531
                                MDC1 rs61733213      43.0% (40/93) (vs. 26.5% \[18/68\])         0.031       0.740

**Note:** *q*-value for adjusted *p*-value with false discovery rate (Benjamini--Hochberg procedure).

**Abbreviations:** CEA, carcinoembryonic antigen; LM, liver metastases.

###### 

Prevalent mutations in synchronous and metachronous groups

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prevalent mutations in synchronous group   Prevalent mutations in metachronous group                                      
  ------------------------------------------ ---------------------------------------------------------------- ------------- -----------------------------------------------------------------
  EGFR\                                      79.5 (vs. 72.1)                                                  EGFR\         72.1 (vs. 79.6)
  rs2227983                                                                                                   rs2227983     

  ATAD3B\                                    78.4[\*\*](#tfn6-cmar-10-2871){ref-type="table-fn"} (vs. 13.2)   RBMXL3\       72.1[\*\*](#tfn6-cmar-10-2871){ref-type="table-fn"} (vs. 53.8)
  rs860213                                                                                                    rs12399211    

  TAPBP\                                     7.84 (vs. 70.6)                                                  TAPBP\        70.6 (vs. 78.5)
  rs2071888                                                                                                   rs2071888     

  ZNF462\                                    71.0 (vs. 67.6)                                                  ZNF462\       67.6 (vs. 71.0)
  rs3814538                                                                                                   rs3814538     

  TCF3\                                      71.0[\*](#tfn5-cmar-10-2871){ref-type="table-fn"} (vs. 47.1)\    PTPN23\       67.6[\*\*](#tfn6-cmar-10-2871){ref-type="table-fn"} (vs. 21.5)\
  rs2074888\                                 68.8[\*](#tfn5-cmar-10-2871){ref-type="table-fn"} (vs. 33.8)     c.3361A\>T\   66.2 (vs. 63.4)
  MAP3K19\                                                                                                    PTCH1\        
  rs3905317                                                                                                   rs357564      

  CUL9\                                      66.7 (vs. 61.7)                                                  CUL9\         61.7 (vs. 66.7)
  rs2273709                                                                                                   rs2273709     

  MAP3K19\                                   66.7[\*\*](#tfn6-cmar-10-2871){ref-type="table-fn"} (vs. 33.8)   MDC1\         60.3[\*\*](#tfn6-cmar-10-2871){ref-type="table-fn"} (vs. 18.3)
  rs1112542                                                                                                   rs61733213    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*p*\<0.05;

*p*\<0.001.

###### 

Univariate and multivariate analyses of latency of metachronous colorectal liver metastases

  Mutation                               Univariate analyses   Multivariate analyses                       
  ------------------- ------------------ --------------------- ----------------------- ------------------- -------
  EGFR rs2227983      Wild-type/mutant   0.43 (0.23--0.78)     0.006                   0.47 (0.25--0.88)   0.019
  RBMXL3 rs12399211   Wild-type/mutant   0.36 (0.19--0.67)     0.001                   0.41 (0.18--0.92)   0.030
  TAPBP rs2071888     Wild-type/mutant   0.49 (0.28--0.85)     0.011                   0.71 (0.36--1.40)   0.324
  PTPN23 c.3361A\>T   Wild-type/mutant   0.49 (0.28--0.87)     0.015                   1.71 (0.64--4.56)   0.287
  PTCH1 rs357564      Wild-type/mutant   0.39 (0.22--0.069)    0.001                   0.50 (0.28--0.91)   0.022
  MDC1 rs61733213     Wild-type/mutant   0.56 (0.33--0.95)     0.033                   0.88 (0.38--2.04)   0.760

**Abbreviation:** HR, hazard ratio.

[^1]: These authors contributed equally to this work
